ReViral names Pharmasset founder as board member
This article was originally published in Scrip
Cardiff, UK-based ReViral, an antiviral drug discovery and development company focused on diseases caused by the respiratory syncytial virus (RSV), has named Professor Raymond Schinazi to its board as a non-executive director – effective from 9 April 2014. Professor Schinazi is the founder of several biotechnology companies including Pharmasset (acquired by Gilead, January 2012), where he chaired the company's board during the discovery of hepatitis C drug Sovaldi (sofosbuvir).
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.